Related Experiment Video
Updated: May 25, 2025
Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice
Published on: April 10, 2019
Cardiac treatment for Duchenne muscular dystrophy: consensus recommendations from the ACTION muscular dystrophy
Paul Esteso1, Scott R Auerbach2, Neha Bansal3
1Cardiology, Boston Children's Hospital, Boston, MA, USA.
Insights
This expert opinion provides crucial guidance on initiating and optimizing cardiac medications for Duchenne muscular dystrophy patients to improve heart health and quality of life.
Area of Science:
- Cardiology
- Neuromuscular Disorders
- Pharmacology
Background:
- Duchenne muscular dystrophy (DMD) is a severe neuromuscular disease leading to progressive cardiomyopathy due to dystrophin loss.
- Current cardiac care for DMD has gaps in medication initiation and optimization strategies.
- Effective management of DMD-associated cardiomyopathy is critical for patient outcomes.
Purpose of the Study:
- To address the critical gap in cardiac care for Duchenne muscular dystrophy.
- To provide expert-derived recommendations for cardiac medication management in DMD.
- To establish a standardized framework for managing DMD-associated cardiomyopathy.
Main Methods:
- This document presents an expert opinion statement.
- Recommendations are based on the expertise of the Advance Cardiac Therapies Improving Outcomes Network.
- Guidance is informed by established guidelines from major cardiovascular and Duchenne muscular dystrophy organizations.
Main Results:
- Comprehensive recommendations for the initiation, titration, and optimization of cardiac medications in DMD are presented.
- Specific guidance addresses disease progression and patient response to therapy.
- The goal is to improve therapeutic efficacy for DMD-associated cardiomyopathy.
Conclusions:
- Standardized cardiac care is essential for improving outcomes in Duchenne muscular dystrophy.
- This expert opinion provides a roadmap for optimizing cardiac medication timing and dosage.
- Implementing these recommendations can enhance cardiac prognosis and quality of life for individuals with DMD.
Introduction:
Duchenne muscular dystrophy is a devastating neuromuscular disorder characterized by the loss of dystrophin, inevitably leading to cardiomyopathy. Despite publications on prophylaxis and treatment with cardiac medications to mitigate cardiomyopathy progression, gaps remain in the specifics of medication initiation and optimization.
Method:
This document is an expert opinion statement, addressing a critical gap in cardiac care for Duchenne muscular dystrophy. It provides thorough recommendations for the initiation and titration of cardiac medications based on disease progression and patient response. Recommendations are derived from the expertise of the Advance Cardiac Therapies Improving Outcomes Network and are informed by established guidelines from the American Heart Association, American College of Cardiology, and Duchenne Muscular Dystrophy Care Considerations. These expert-derived recommendations aim to navigate the complexities of Duchenne muscular dystrophy-related cardiac care.
Results:
Comprehensive recommendations for initiation, titration, and optimization of critical cardiac medications are provided to address Duchenne muscular dystrophy-associated cardiomyopathy.
Discussion:
The management of Duchenne muscular dystrophy requires a multidisciplinary approach. However, the diversity of healthcare providers involved in Duchenne muscular dystrophy can result in variations in cardiac care, complicating treatment standardization and patient outcomes. The aim of this report is to provide a roadmap for managing Duchenne muscular dystrophy-associated cardiomyopathy, by elucidating timing and dosage nuances crucial for optimal therapeutic efficacy, ultimately improving cardiac outcomes, and improving the quality of life for individuals with Duchenne muscular dystrophy.
Conclusion:
This document seeks to establish a standardized framework for cardiac care in Duchenne muscular dystrophy, aiming to improve cardiac prognosis.
Related Concept Videos
01:21Satellite Stem Cells and Muscular Dystrophy
01:26Heart Failure Drugs: Inotropic Agents
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:20Exercise and Cardiovascular Response
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...